The Food and Drug Administration (FDA) announced that Rebetol (ribavirin; Merck) capsules and PegIntron
(peginterferon alfa-2b; Merck) for Injection are being discontinued.
The decision is business-related and not due to safety or efficacy
issues with the drugs.
Rebetol is a nucleoside analogue indicated for chronic hepatitis C
in combination with interferon alfa-2b (pegylated and nonpegylated), in
patients ≥3 years of age with compensated liver disease. It is supplied
as 200mg capsules in 56-, 70-, and 84-count bottles. The Rebetol
discontinuation is effective February 1, 2016.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.